You are here

lung cancer

AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs

AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs

Fierce Pharma

Flag link:

Spectrum yanks marketing application for Neulasta rival after FDA demands more data

Spectrum yanks marketing application for Neulasta rival after FDA demands more data

Endpoints

Spectrum Pharmaceuticals

Flag link:

Roche gets European approval for Tecentriq combo vs. lung cancer

Roche gets European approval for Tecentriq combo vs. lung cancer

Reuters

metastatic non-squamous non-small cell lung cancer

Flag link:

J&J bags option on AdoRx lung cancer drugs

J&J bags option on AdoRx lung cancer drugs

Fierce Biotech

drug development

Flag link:

Real-World Data on Medtronic's Lung Cancer Device Is Promising

Real-World Data on Medtronic's Lung Cancer Device Is Promising

Medical Devices and Diagnostics Industry

electromagnetic navigation bronchoscopy

Flag link:

A New Collaboration Could Be Key in the Early Detection of Lung Cancer

A New Collaboration Could Be Key in the Early Detection of Lung Cancer

Medical Devices and Diagnostics Industry

Flag link:

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

BioCentury

Flag link:

Veracyte Finds Ally in J&J for Early Lung Cancer Detection

Veracyte Finds Ally in J&J for Early Lung Cancer Detection

Medical Devices and Diagnostics Industry

genomic diagnostics

Flag link:

New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases

New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases

BioSpace

Bristol-Myers Squibb

Flag link:

Boehringer employees go door-to-door delivering holiday hope to lung cancer patients

Boehringer employees go door-to-door delivering holiday hope to lung cancer patients

Fierce Pharma

Boehringer Ingelheim

Flag link:

AbbVie suffers fresh setback with lung cancer drug Rova-T

AbbVie suffers fresh setback with lung cancer drug Rova-T

Pharmaforum

Flag link:

One more shot at slowing Keytruda’s first-line lung cancer domination

One more shot at slowing Keytruda’s first-line lung cancer domination

EP Vantage

Flag link:

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Flag link:

Common Blood Pressure Medication Linked To Increased Risk Of Lung Cancer

Common Blood Pressure Medication Linked To Increased Risk Of Lung Cancer

Forbes

Flag link:

Just-Announced U.S. and Cuba Biopharma Venture Sees Fruit in Lung Cancer Study

Just-Announced U.S. and Cuba Biopharma Venture Sees Fruit in Lung Cancer Study

BioSpace

Bristol-Myers Squibb

Flag link:

Veracyte to Present Data Supporting Use of Their Non-Invasive Diagnostics for Lung Diseases

Veracyte to Present Data Supporting Use of Their Non-Invasive Diagnostics for Lung Diseases

CP Wire

Percepta Bronchial Genomic Classifier

Flag link:

Veracyte to Present Data Supporting Use of Their Non-Invasive Diagnostics for Lung Diseases

Flag link:

Clovis Oncology to Pay the SEC $20 Million for Misleading Investors

Clovis Oncology to Pay the SEC $20 Million for Misleading Investors

BioSpace

Clovis Oncology

Flag link:

Johnson & Johnson raises a flag in early-stage lung cancer with first-ever contest in the field

Johnson & Johnson raises a flag in early-stage lung cancer with first-ever contest in the field

Fierce Pharma

drug development

Flag link:

In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

Endpoints

Flag link:

Pages